Skip to main content

Table 2 The changes in DM patients' inflammation parameters.

From: Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment

Parameters

HC

Metformin (months)

Rosiglitazone (months)

  

0

1

2

0

2

WBC × 10 9

6.7 ± 0.1

7.3 ± 0.3b

7.4 ± 0.4

7.5 ± 0.2

7.04 ± 0.5b

6.8 ± 0.6

PMNLs × 10 9

4.0 ± 0.1

4.6 ± 0.3b

4.7 ± 0.2

4.9 ± 0.1

4.2 ± 0.4b

4.4 ± 0.5

PMNL apoptosis (%)

4.0 ± 0.1

12.7 ± 3.4b

9.5 ± 2.8a, b

6.5 ± 1.0a

20.4 ± 4.4b

7.5 ± 1.9a

Monocytes × 10 9

0.36 ± 0.02

0.44 ± 0.05b

0.40 ± 0.04b

0.39 ± 0.04a

0.49 ± 0.03b

0.39 ± 0.01a

Fibrinogen (mg/dl)

304.6 ± 17.6

440.1 ± 25.2b

471.1 ± 28.8b

415.9 ± 41.2a, b

400 ± 16.6b

332.8 ± 8.1a,b

Albumin (g/dl)

4.6 ± 0.05

4.53 ± 0.1

4.74 ± 0.1

4.7 ± 0.04

4.5 ± 0.1

4.6 ± 0.1

Transferrin (g/dl)

273.2 ± 10.6

274.6 ± 8.4

276.7 ± 7.2

287.9 ± 7.7

264.7 ± 7.6

286.2 ± 8.9

CRP (mg/L)

1.5 ± 0.1

8.3 ± 1.6b

6.6 ± 1.1b

5.8 ± 1.5a, b

4.3 ± 0.9b

1.8 ± 0.2a,b

  1. a P < 0.05, treated DM patients vs. untreated DM patients;
  2. b P < 0.05, untreated DM patients vs. HC subjects